Survey and analysis of the concerns of patients with chronic myeloid leukemia in China in 2021
10.3760/cma.j.issn.0253-2727.2022.09.008
- VernacularTitle:2021年中国慢性髓性白血病患者关注的问题调查与分析
- Author:
Yuting LIU
1
;
Xiaoshuai ZHANG
;
Yue HOU
;
Qian JIANG
Author Information
1. 北京大学人民医院、北京大学血液病研究所、国家血液系统疾病临床医学研究中心，北京 100044
- Keywords:
Chronic myeloid leukemia (CML);
Tyrosine kinase inhibitor (TKI);
Patients’ concerns;
Questionnaire investigation
- From:
Chinese Journal of Hematology
2022;43(9):760-765
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the concerns of adult patients with chronic myeloid leukemia (CML) in the chronic phase receiving tyrosine kinase inhibitor (TKI) therapy in China.Methods:A cross-sectional questionnaire including 23 issues of concern was filled by patients with CML nationwide from August to September 2021. The results were compared with those from 2015 to 2016.Results:Data from 952 questionnaires were analyzed. The five most concerned issues were "TKI-related adverse effects and management" (66%) , "stopping TKI therapy" (46%) , "CML risk assessment" (46%) , "TKI dose reduction" (42%) , and "restrictions in daily life activities" (41%) . Compared with the results from 2015 to 2016, patients paid more attention to "TKI-related adverse effects and management" , "monitoring" , and "interpretation of laboratory reports" (all P<0.01) . Concerns of "TKI reimbursement policies" , "price reduction of TKIs" , and issues related to generic TKIs decreased significantly (all P<0.01) . Multivariate analysis showed that female patients ( OR=1.8, 95% CI 1.4-2.5, P<0.001) , elderly patients ( OR=1.0, 95% CI 1.0-1.0, P<0.001) , or patients with bachelor's degree or higher ( OR=1.8, 95% CI 1.3-2.4, P<0.001) were more concerned with "TKI dose reduction" than others. Patients with a bachelor’s degree or higher ( OR=1.6, 95% CI 1.2-2.2, P=0.002) paid more attention to "CML risk assessment" , whereas those currently receiving a second- or third-generation TKI therapy ( OR=1.9, 95% CI 1.3-2.6, P<0.001) were more concerned about "TKI resistance" . Conclusion:Patients with CML paid the most attention to "TKI-related adverse effects and management" , "stopping TKI therapy" , "CML risk assessment" , "TKI dose reduction" , and "restrictions in daily life activities" . Patients' sociodemographic covariates and treatment status were associated with their concerns.
